Emerging concepts in metabolic abnormalities associated with coronary artery disease

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Current Opinion in Cardiology

• Publication date

  2000-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00001573-200011000-00008PMID 11198624
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

  2000cited by this paper
• Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms

  2000cited by this paper
• The Nobel chronicles. 1985: Joseph Leonard Goldstein (b 1940), Michael Stuart Brown (b 1941).

  2000cited by this paper
• MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION

  2000cited by this paper
• 胰岛素增敏剂一Thiazolidinediones研究现状

  2000cited by this paper
• LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study.

  2000cited by this paper
• Risk Factors for Coronary Heart Disease in Diabetes

  2000cited by this paper
• Implications of the UK Prospective Diabetes Study

  2000cited by this paper
• Peroxisome proliferator‐activated receptors in the cardiovascular system

  2000cited by this paper
• Long-Term Prevention of Bone Loss

  2000cited by this paper
• Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study).

  2000cited by this paper
• Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

  1999cited by this paper
• Metabolic risk factors for coronary heart disease: current and future prospects.

  1999cited by this paper
• Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study.

  1999cited by this paper
• Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

  1999cited by this paper
• Epidemiology of insulin resistance and its relation to coronary artery disease.

  1999cited by this paper
• Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

  1999cited by this paper
• Atherosclerotic plaque rupture: emerging insights and opportunities.

  1999cited by this paper
• Pharmacologic Therapy for Type 2 Diabetes Mellitus

  1999cited by this paper
• PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.

  1999cited by this paper
• Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging.

  1999cited by this paper
• Histological and ultrastructural features of atherosclerosis in progeria.

  1999cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• Patients with type 2 diabetes: the case for primary prevention.

  1999cited by this paper
• Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment.

  1999cited by this paper
• Anitschkow and the cholesterol over-fed rabbit.

  1999cited by this paper
• A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering

  1999cited by this paper
• PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells

  1999cited by this paper
• Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment

  1999cited by this paper
• Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

  1999cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• The sulfonylurea controversy: more questions from the heart.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Epidemiology of Type 2 Diabetes: Risk Factors

  1998cited by this paper
• PPARgamma in monocytes: less pain, any gain?

  1998cited by this paper
• Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

  1998cited by this paper
• Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.

  1998cited by this paper
• PPARγ in Monocytes: Less Pain, Any Gain?

  1998cited by this paper
• Treatment of diabetic dyslipidemia.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Another potential use of troglitazone in noninsulin-dependent diabetes mellitus.

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• THIAZOLIDINEDIONES: TOOLS FOR THE RESEARCH OF METABOLIC SYNDROME X

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Insulin resistance: current concepts.

  1998cited by this paper
• THE EFFECT of AGE on INSULIN RESISTANCE and SECRETION

  1998cited by this paper
• Treatment of diabetes mellitus to reduce its chronic cardiovascular complications.

  1998cited by this paper
• Diabetes mellitus and cardiovascular disease in women.

  1998cited by this paper
• Thiazolidinediones.

  1997cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• Banting Lecture 1988. Role of insulin resistance in human disease. 1988.

  1997cited by this paper
• Impaired Glucose Tolerance, Insulin Resistance and Cardiovascular Disease

  1997cited by this paper
• Insulin resistance implications for type II diabetes mellitus and coronary heart disease.

  1997cited by this paper
• The Scandinavian Simvastatin Survival Study (4S) Subgroup Analysis of Diabetic Subjects: Implications for the Prevention of Coronary Heart Disease

  1997cited by this paper
• Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation.

  1997cited by this paper
• Mechanisms Determining Course and Outcome of Diabetic Patients Who Have Had Acute Myocardial Infarction

  1997cited by this paper
• Insulin resistance, its consequences, and coronary heart disease. Must we choose one culprit?

  1996cited by this paper
• Cardiovascular risk factors and the prediabetic syndrome.

  1996cited by this paper
• The effect of age on insulin resistance and secretion: a review.

  1996cited by this paper
• Historical review of research on atherosclerosis.

  1995cited by this paper
• Pathophysiology of insulin resistance in human disease.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

  1993cited by this paper

• Antihyperlipidemic Effect of Flavonoids and Saponins from Pyracantha fortuneana Fruits on L02 Cells and Caenorhabditis elegans

  2025cites this paper
• Cyclosorus terminans Extract Ameliorates Insulin Resistance and Non-Alcoholic Fatty Liver Disease (NAFLD) in High-Fat Diet (HFD)-Induced Obese Rats

  2022cites this paper
• Beneficial Effects of SREBP Decoy Oligodeoxynucleotide in an Animal Model of Hyperlipidemia

  2020cites this paper
• Genipin alleviates high‐fat diet‐induced hyperlipidemia and hepatic lipid accumulation in mice via miR‐142a‐5p/SREBP‐1c axis

  2018cites this paper
• PPARα receptor expression in patients with metabolic syndrome.

  2018cites this paper
• Hypolipidemic effect of oleanolic acid is mediated by the miR‐98‐5p/PGC‐1β axis in high‐fat diet‐induced hyperlipidemic mice

  2017cites this paper
• Fucoidan improves serum lipid levels and atherosclerosis through hepatic SREBP-2-mediated regulation.

  2016cites this paper
• Rubus crataegifolius Bunge regulates adipogenesis through Akt and inhibits high-fat diet-induced obesity in rats

  2016cites this paper
• Peroxisome Proliferator‐Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies

  2016cites this paper
• 4-Hydroxyisoleucine from Fenugreek (Trigonella foenum-graecum): Effects on Insulin Resistance Associated with Obesity

  2016cites this paper
• Aging and dyslipidemia: a review of potential mechanisms.

  2015cites this paper
• Effects of the traditional medicine, Dai-Ken-Chu-To on obesity and glucose intolerance induced by long-term feeding on a high-fat diet in mice

  2015cites this paper
• Chemical and toxicological characterization of chemical contaminants in air pollution particulate matter

  2015cites this paper
• Saroglitazar, a novel cardiometabolic agent for diabetic dyslipidemia – A Review

  2014cites this paper
• Saroglitazar: India's Answer to Diabetic Dyslipidemia

  2014cites this paper
• Anti-obesity effects of glabridin-rich supercritical carbon dioxide extract of licorice in high-fat-fed obese mice.

  2013cites this paper
• Hop (Humulus lupulus L.) extract inhibits obesity in mice fed a high-fat diet over the long term

  2012cites this paper
• Beneficial effects by intake of Euphausiacea pacifica on high-fat diet-induced obesity.

  2012cites this paper
• Relationship between Plasma Lipids and Osteoporosis in Korean Postmenopausal Women

  2011cites this paper
• Two unhealthy dietary habits featuring a high fat content and a sucrose-containing beverage intake, alone or in combination, on inducing metabolic syndrome in Wistar rats and C57BL/6J mice.

  2011cites this paper
• Dual acting and pan-PPAR activators as potential anti-diabetic therapies.

  2011cites this paper
• Upregulation of Lipogenesis and Protein Tyrosine Phosphatase-1B Expression in the Liver of Wistar Rats with Metabolic Syndrome Chronically Induced by Drinking Sucrose Water

  2010cites this paper
• Relación Estructura-Función de apolipoproteínas plasmáticas

  2010cites this paper
• Waist-to-hip ratio is a better anthropometric index than body mass index for predicting the risk of type 2 diabetes in Taiwanese population.

  2010cites this paper
• The metabolic benefits of Polygonum hypoleucum Ohwi in HepG2 cells and Wistar rats under lipogenic stress.

  2010cites this paper
• Optimal cutoff value of high-density lipoprotein cholesterol for predicting coronary artery disease in Taiwanese population.

  2010cites this paper
• Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice.

  2010cites this paper
• Nonfasting Lipemia and Inflammation as Cardiovascular Disease Risks After SCI

  2009cites this paper
• A herbal extract with acetyl-coenzyme A carboxylase inhibitory activity and its potential for treating metabolic syndrome.

  2009cites this paper
• The functional assessment of Alpinia pricei on metabolic syndrome induced by sucrose‐containing drinking water in mice

  2009cites this paper
• Chronic intake of a high-cholesterol diet resulted in hepatic steatosis, focal nodular hyperplasia and fibrosis in non-obese mice

  2009cites this paper
• PPARs in Atherosclerosis

  2008cites this paper
• Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats

  2008cites this paper
• Peroxisome proliferator activated receptors and their role in reproduction.

  2008cites this paper
• Risk analysis of coronary heart diseases in Korean adults by using the National Cholesterol Education Program Adult Treatment Panel III

  2007cites this paper
• International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors

  2006cites this paper
• Chronic intake of high-fat and high-sucrose diets differentially affects glucose intolerance in mice.

  2006cites this paper
• Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18

  2006cites this paper
• Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18.

  2006cites this paper
• Associação entre a densidade mineral óssea da coluna lombar e do fêmur e do perfil lipídico e lipoprotéico em pacientes pós-menopáusicas com osteoporose

  2006cites this paper
• Dual PPARα/γ Ligand TZD18 Either Alone or in Combination with Imatinib Inhibits Proliferation and Induces Apoptosis of Human CML Cell Lines

  2006cites this paper
• Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability.

  2006cites this paper
• Growth inhibition and apoptosis in human Philadelphia chromosome – positive lymphoblastic leukemia cell lines by treatment with the dual PPAR / ligand TZD 18

  2006cites this paper
• PPAR ligands: Potential therapies for metabolic syndrome

  2005cites this paper
• PPARs: therapeutic targets for metabolic disease.

  2005cites this paper
• In search of new structural states of exchangeable apolipoproteins.

  2004cites this paper
• Breakthroughs and Views In search of new structural states of exchangeable apolipoproteins

  2004cites this paper
• The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.

  2003cites this paper
• Emerging importance of HDL cholesterol in developing high‐risk coronary plaques in acute coronary syndromes

  2003cites this paper
• Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation.

  2003cites this paper
• Ultrasonic Imaging of Myocardial Strain Using Cardiac Elastography

  2003cites this paper
• Peroxisome proliferator-activated receptors

  2002cites this paper
• Plasma lipids and osteoporosis in postmenopausal women.

  2002cites this paper
• Early clinical development of pharmaceuticals for type 2 diabetes mellitus: from preclinical models to human investigation.

  2002cites this paper
• The mechanisms of action of PPARs.

  2002cites this paper
• High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.

  2002cites this paper
• PPARα and Atherosclerosis

  2002cites this paper
• Structures of apolipoprotein A-II and a lipid-surrogate complex provide insights into apolipoprotein-lipid interactions.

  2002cites this paper
• Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors

  2002cites this paper
• A REPORT BY THE CARDIOVASCULAR DIVISION OF BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MASSACHUSETTS Cardiology Cardiology SCIENTIFIC UPDATE SCIENTIFIC UPDATE

  2001cites this paper
• Myocardial Infarction in the Younger Patient

  1999cites this paper
• Secondary Prevention of Myocardial Infarction

  1999cites this paper
• Review Article Peroxisome Proliferator-activated Receptor Targets for the Treatment of Metabolic Diseases

  year unknowncites this paper